Quantitative Analysis of β-Amyloid Peptides Expressed in Human Cerebrospinal Fluid by an Improved Method of Antibody-Assisted Time-of-Flight Mass Spectrometry
Quantitative Analysis of β-Amyloid Peptides Expressed in Human Cerebrospinal Fluid by an Improved Method of Antibody-Assisted Time-of-Flight Mass Spectrometry
复制标题
采用改进的抗体辅助飞行时间质谱法定量分析人脑脊液中表达的 β-淀粉样肽
DOI：
10.1007/s10989-009-9174-3
复制
发表时间：
2009
影响因子：
2.5
通讯作者：
O. Midorikawa
中科院分区：
文献类型：
--
作者：
Akira Matsumoto;R. Matsumoto;K. Kadoyama;Taka;S. Matsuyama;O. Midorikawa
建立早期阿尔茨海默病（AD）和轻度认知障碍（MCI）的诊断方法至关重要。使用表面增强激光解吸电离飞行时间质谱（SELDI-TOF-MS），抗体辅助脑脊液（CSF）质谱能够定量分析β-淀粉样蛋白（a β）肽的比例，a β1-42/ a β1-40，这对AD/MCI具有诊断价值。为了将质谱分析应用于更广泛的脑脊液样品，我们建立了一种定量分析100 μl脑脊液样品中表达的a β肽的方法。通过限制过滤预处理脑脊液样品以浓缩肽，并使用尿素作为变性剂修改洗涤程序，感兴趣的Aβ肽可以以比原始方法高5到10倍的灵敏度进行评估。这一改进使得能够从剩余的脑脊液样本中定量分析a β物种，这将在手术前腰椎麻醉和常规诊断目的进行脊髓穿刺的情况下偶尔获得。作为实验室检查的新程序的流行，特别是在老年神经科门诊咨询中，将增加早期诊断为AD/MCI的受试者数量。
Establishment of diagnostic measures for early stage Alzheimer’s disease (AD) and mild cognitive impairment (MCI) is of crucial importance. Using surface enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI-TOF-MS), antibody-assisted MS of cerebrospinal fluid (CSF) has enabled quantitative analysis of the ratio of β-amyloid (Aβ) peptides, Aβ1-42/Aβ1-40, which has a diagnostic value for AD/MCI. To apply the MS analysis to a far wider range of CSF samples, we have established a method to analyze Aβ peptides expressed in 100 μl CSF samples quantitatively. Pretreatment of CSF samples by limit-filtration to condense peptides, and modified washing procedure using urea as denaturant, Aβ peptides of interest can be assessed with higher sensitivity by five to tenfolds to the original method. This improvement enables quantitative analysis of Aβ species from a residual amount of CSF samples, which will be occasionally obtained in case of lumbar anesthesia prior to operation and spinal tap performed for routine diagnostic purposes. Prevalence of the new procedure as laboratory test, especially among the elderly consulting for neurological clinic, will enhance the number of subjects diagnosed at early stage of AD/MCI.
影响因子：
158.5
作者：
Petersen, RC;Thomas, RG;Thal, LJ
通讯作者：
Thal, LJ
影响因子：
6
作者：
Praticò, D;Zhukareva, V;Lee, VMY
通讯作者：
Lee, VMY
影响因子：
15.9
作者：
Cirrito, JR;Deane, R;Holtzman, DM
通讯作者：
Holtzman, DM